Eli Lilly said on Thursday it would appeal against a UK agency's recommendation to not reimburse the cost of Alzheimer's drug ...

Two breakthrough Alzheimer's drugs have been deemed far too expensive, for too little benefit, to be offered on the NHS. The ...

Secretary of Agriculture Brooke Rollins on Wednesday announced a plan to enhance the agency's ability to detect, control and ...

A study published in The BMJ compares the evidence around intermittent fasting and calorie restriction for weight loss. Prof Maik Pietzner, Chair in Health Data Modelling, Queen Mary University of ...

Corsi and DiMeglio are both responsible for leading marketing and growth strategies for their distinct companies. Corsi is ...

Reale, a rookie with the NWSL's Gotham FC, has previously represented the US at the U-17, U-20, and U-23 levels.

A senior scientist at the U.S. Centers for Disease Control and Prevention has resigned, warning that changes in leadership ...

Scholar Rock's latest trial returned very positive results. Shares of Scholar Rock Holding (NASDAQ: SRRK) are soaring today, ...

Shares of Scholar Rock Holdings jumped Wednesday after the biopharmaceutical firm reported positive results from a ...

In combination with Eli Lilly’s tirzepatide, marketed as Zepbound for obesity, Scholar Rock’s monolonal antibody helped ...

Scholar Rock's apitegromab helped preserve muscle mass during tirzepatide-induced weight loss, improving overall body ...

On the sidelines of BIO2025, Julie Gilmore, head of Lilly Gateway Labs, shares her thoughts on the $1.3 billion Verve Therapeutics buy, where Lilly’s therapeutic puck is potentially going and how the ...